Clinical Trial Update: The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the efficacy of enavogliflozin in heart failure with preserved ejection fraction (HFpEF).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Enavogliflozin (enavogliflozin)

Snippet

Sponsor: Samsung Medical Center | Conditions: Heart Failure, Preserved Ejection Fraction | Phase 4 | Status: NOT_YET_RECRUITING